Qutenza Patch - Our early experience
| dc.contributor.author | Weekes, G | |
| dc.contributor.author | O’Brien, J | |
| dc.contributor.author | Murphy, K | |
| dc.contributor.author | Keavney, J | |
| dc.contributor.author | Pollard, V | |
| dc.date.accessioned | 2013-03-21T13:56:49Z | |
| dc.date.available | 2013-03-21T13:56:49Z | |
| dc.date.issued | 2013-03 | |
| dc.identifier.uri | http://hdl.handle.net/10147/275594 | |
| dc.description.abstract | Qutenza is a high potency capsaicin topical patch which has been recommended for the treatment of peripheral neuropathic pain. The aim of this study was to assess our selected patients’ response to Qutenza application. All patients had their dynamic pain score recorded prior to application and were asked to fill in a standardised questionnaire for three months post application. Patients were also asked to document any changes to the character of their pain, changes in sleep, activities of daily living and mood as well as any changes to their medication usage. 21 patients had Qutenza applied in a 5 month period. 17 patients completed the questionnaire in a 5 month period. We found that the mean overall reduction in pain score at 3 months was 32.7%. 8 of our patients (47%) reported improved sleep, activities of daily living and mood. 6 patients (35%) reported a reduction in medication use, while 7 (41%) reported an improvement in the character of their pain | |
| dc.language.iso | en | en |
| dc.publisher | Irish Medical Journal | en_GB |
| dc.subject | PAIN MANAGEMENT | en_GB |
| dc.title | Qutenza Patch - Our early experience | en_GB |
| dc.type | Article | en |
| dc.identifier.journal | Irish Medical Journal | en_GB |
| dc.description.province | Leinster | en |
| refterms.dateFOA | 2018-08-23T04:11:35Z | |
| html.description.abstract | Qutenza is a high potency capsaicin topical patch which has been recommended for the treatment of peripheral neuropathic pain. The aim of this study was to assess our selected patients’ response to Qutenza application. All patients had their dynamic pain score recorded prior to application and were asked to fill in a standardised questionnaire for three months post application. Patients were also asked to document any changes to the character of their pain, changes in sleep, activities of daily living and mood as well as any changes to their medication usage. 21 patients had Qutenza applied in a 5 month period. 17 patients completed the questionnaire in a 5 month period. We found that the mean overall reduction in pain score at 3 months was 32.7%. 8 of our patients (47%) reported improved sleep, activities of daily living and mood. 6 patients (35%) reported a reduction in medication use, while 7 (41%) reported an improvement in the character of their pain |
